VRTX · News · 20260817N
Revenue Performance and Mix
VERTEX PHARMACEUTICALS INC / MA · 2026-08-17 · Importance 47 · Surprise 22 · No source text
Vertex reported quarterly revenue of $3.33 billion, exceeding analyst estimates. Revenue increased 12.5% year over year during the quarter. The company narrowly missed consensus EPS at $4.73 despite the revenue outperformance.
Key facts
- Vertex Pharmaceuticals reported a 12.5% year-over-year revenue increase for the quarter. source
- Vertex Pharmaceuticals reported quarterly revenue of $3.33 billion, exceeding estimates. source
- Vertex Pharmaceuticals has a market capitalization of $128.36 billion. source
- Vertex Pharmaceuticals reported quarterly earnings per share (EPS) of $4.73, which narrowly missed analyst estimates. source
- Analysts have a consensus 'Moderate Buy' rating on Vertex Pharmaceuticals with an average target price of $563.50. source
- Vertex Pharmaceuticals' 12-month trading range shows a low of $374.17 and a high of $546.17. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +11.1% | Vertex Pharmaceuticals reported a 12.5% year-over-year revenue increase for the quarter. |